Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basiliximab in liver transplantation for HCV+ patients
NCT00238901Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2002
- Primary completion
- Jul 2005
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of basiliximab in Graft loss (GF), graft rejection, sponsored by Novartis. Started Dec 2002; status: completed.
02
Drugs
basiliximab
03
Conditions
Graft loss (GF)graft rejection
Beyond the preview
Go deeper on NCT00238901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238901.